| Issuer | % of Class | Filed |
|---|---|---|
|
Chemomab Therapeutics Ltd.
13G/A
Amendment 3
GLTO · 36322Q107
|
1.2% |
8/10/2026
Event 8/10/2026
|
|
Chemomab Therapeutics Ltd.
13G/A
Amendment 2
GLTO · 36322Q107
|
6.3% |
2/10/2026
Event 2/10/2026
|
|
Chemomab Therapeutics Ltd.
13G/A
Amendment 1
GLTO · 36322Q107
|
8.1% |
8/11/2025
Event 8/11/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.